Humanigen, Inc., (OTCQB:HGEN), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced today the pricing of a private placement of approximately $72 million of common stock. J.P. Morgan Securities LLC is acting as the placement agent for the financing, which comprises a group of healthcare investors including Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), HealthCor, Valiant Capital Partners, First Light Asset Management and Ghost Tree Capital.
CLICK HERE to see full article
Mark Cohen, Senior Partner and Chair of the Life Sciences Practice Group, and Elizabeth Wieckowski represent Humanigen in its intellectual property matters.
